Radiopharm (ASX: RAD) Strengthens Scientific Advisory Board with Renowned Prostate Cancer Expert

July 21, 2025 06:32 PM PDT | By Aditi Sarkar

Google News:

Radiopharm (ASX: RAD) Strengthens Scientific Advisory Board with Renowned Prostate Cancer Expert — Image source: RAD Update

Recent News

Retailnow And The Kiosk Industry Association – Visit Booth 445 For Ai...

Entegris (NASDAQ:ENTG) Momentum Powers Indexnasdaq IXIC in Latest Mark...

Brazil economists trim 2026 inflation forecast for first time in over...

Market Reactions NYSE Composite and Ellington Financial Latest Update

Highlights

Dr Oliver Sartor has been appointed to Radiopharm’s Scientific Advisory Board, strengthening the company’s clinical leadership.

Dr Sartor is a globally recognised expert in prostate cancer and radiopharmaceutical therapies.

He currently serves as Director at Mayo Clinic and has held senior academic posts at top U.S. institutions.

His clinical research has contributed to FDA approvals for multiple prostate cancer therapies, including PSMA-targeted treatment.

Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX) has strengthened its scientific leadership with the appointment of Dr Oliver Sartor, MD, to its Scientific Advisory Board. A globally recognised medical oncologist and scientist, Dr Sartor brings decades of expertise in prostate cancer and radiopharmaceutical therapies to the company.

Prostate Cancer Research Leader with Decades of Experience

Dr Oliver Sartor earned his MD with honours from Tulane University School of Medicine in 1982, followed by an internal medicine residency at Tulane and a medical oncology fellowship at the National Cancer Institute (NCI). Since 1990, his work has centred on prostate cancer clinical research.

Throughout his career, Dr Sartor has authored over 500 peer-reviewed publications and played a key role in multiple pivotal Phase 3 clinical trials, contributing to the FDA approval of treatments such as samarium 153 EDTMP, cabazitaxel, radium 223, and PSMA-targeted radioligand therapy.

His appointment has been described as a significant addition to Radiopharm’s Scientific Advisory Board, with his expertise in clinical translation and radiopharmaceutical therapies regarded as unparalleled. “We’re very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline,” said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics.

The share price of RAD was AUD 0.023 at the time of writing on 22 July 2025.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.